University of Rochester

Labster Opens Registration for May 29-30 Science ImmersEd Conference

Retrieved on: 
Martedì, Maggio 14, 2024
Science, Software, Other Science, Other Education, Continuing, Technology, Education, Training, Labrinth discography, Time (magazine), STEM, Faculty, Student, Lecture, TIME, Language, University, University of Saint Joseph, EDT, Book, Conference, University of Westminster, University of Louisville, University of Rochester, Georgia Tech, Bowdoin College, Alamance Community College, Human, Multimedia, Community college, Tutoring

Labster ( www.labster.com ), which offers the world's leading edtech platforms for immersive digital simulations, is introducing Science ImmersEd , a professional development conference for the science educator community.

Key Points: 
  • Labster ( www.labster.com ), which offers the world's leading edtech platforms for immersive digital simulations, is introducing Science ImmersEd , a professional development conference for the science educator community.
  • “The Labster Science ImmersEd Conference is our way of giving back — and paying tribute to — the many dedicated members of the Labster STEM community.
  • Live attendees at the online Science ImmersEd Conference receive related bonus content and access to short videos of conference highlights and key takeaways.
  • Check out the full two-day agenda for the free Labster Science ImmersEd virtual conference and register to attend: https://www.labster.com/science-immersed#Agenda .

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Chicago Medical School, Sale, University, Patient, Rutgers University, ATS, Alopecia areata, Kinetics, Skin, European Patent Convention, Research, MD, Doctor of Philosophy, Conference, KOL, Potential, ADS, Week, Patent, Data, Dupilumab, University of Rochester, Translational medicine, International Examiner, Magnetic resonance, Atopic dermatitis, Harvard Medical School, ASLN, TREK, Clutch (eggs), Interim, Biology, American Thoracic Society, Associate, Emergency medicine, EPO, SAN, COPD, Pharmaceutical industry

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
  • Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023.
  • General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023.
  • Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

Retrieved on: 
Martedì, Maggio 7, 2024
Chicago Medical School, Itch, University, Patient, Skin, MD, Doctor of Philosophy, KOL, Potential, Week, Data, University of Rochester, Physician, Magnetic resonance, Atopic dermatitis, ASLN, Clutch (eggs), SAN, Pharmaceutical industry

“The numbers we have reported from the interim analysis of the TREK-DX study are unprecedented in previous biologics studies in atopic dermatitis (AD) and the new data continue to support our original conclusions announced in April.

Key Points: 
  • “The numbers we have reported from the interim analysis of the TREK-DX study are unprecedented in previous biologics studies in atopic dermatitis (AD) and the new data continue to support our original conclusions announced in April.
  • During the KOL event today, Company management will present new data on investigator-assessed and patient-reported secondary endpoints and data from the subgroup of patients with prior inadequate response to dupilumab.
  • Discontinuation rates were lower for patients treated with eblasakimab (13%, 2/15) compared to those on placebo (43%, 3/7).
  • Waterfall plots of individual patient responses show clear and consistent improvements in almost all patients treated with eblasakimab versus placebo.

Rally House Opens First Store in Buffalo, NY

Retrieved on: 
Venerdì, Aprile 26, 2024
Buffalo Bisons, Buffalo Bills, Sport, Walden Galleria, Ness, Mitchell & Ness, Buffalo Niagara International Airport, Cutter & Buck, Nike, Starter, University of Rochester, Syracuse Orange, Department store

BUFFALO, N.Y., April 26, 2024 /PRNewswire/ -- Rally House, a national sports and merchandise retailer, is excited to have their doors open at the first storefront location in Buffalo, NY, with Rally House Walden Galleria.

Key Points: 
  • BUFFALO, N.Y., April 26, 2024 /PRNewswire/ -- Rally House, a national sports and merchandise retailer, is excited to have their doors open at the first storefront location in Buffalo, NY, with Rally House Walden Galleria.
  • Shoppers can find Rally House Walden Galleria inside the mall on the upper level near the food court and across from Zara.
  • Rally House, who was recently rated by Yelp as the fastest growing sports and merchandise retailer in the nation, is thrilled to expand their company footprint into Buffalo, NY.
  • The company recommends that customers visit the Rally House Walden Galleria store page and follow on Facebook ( @RallyHouse ) and Instagram ( @rally_house ) for current store information and updates.

HF Foods Appoints Cindy Yao as Chief Financial Officer

Retrieved on: 
Giovedì, Aprile 25, 2024
University, Corning Inc., Business administration, Literature, Growth, PwC, East China Normal University, Cooper, University of Rochester, Certified Treasury Professional, Language, Virginia Tech, HF, Management

LAS VEGAS, April 25, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods”, or the “Company”), a leading food distributor to Asian restaurants across the United States, today announced that Cindy Yao has been named Chief Financial Officer, effective May 1, 2024.

Key Points: 
  • LAS VEGAS, April 25, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods”, or the “Company”), a leading food distributor to Asian restaurants across the United States, today announced that Cindy Yao has been named Chief Financial Officer, effective May 1, 2024.
  • “Cindy's extensive experience, especially having spent a decade directing financial operations for a company serving food producers, makes her an invaluable addition to HF Foods,” said Peter Zhang, Chief Executive Officer of HF Foods.
  • “Her proven track record of streamlining processes using data-driven decision making to drive growth aligns perfectly with HF Foods.
  • Ms. Yao will join the HF Foods executive leadership team and be based out of the Company’s headquarters in Las Vegas, Nevada.

Glen-Gery Launches First U.S. Exclusive Edition of Materiality Showcasing Contemporary University Architecture

Retrieved on: 
Giovedì, Aprile 18, 2024
University, Learning, Computer science, Vanderbilt University, Data science, University of Rochester, Movement, Beauty, Marketing, Season, Creativity, Student, Ibstock plc, Engineering, Interior design

WYOMISSING, Pa., April 18, 2024 /PRNewswire/ -- Glen-Gery Corporation, a premier brick manufacturer that is part of Brickworks North America, is pleased to launch the first U.S. exclusive edition of Materiality, a publication that explores the use of bricks in contemporary architecture. Materiality is intended to provoke discussion and interest among architects and designers, professionals and students, and the general reader.

Key Points: 
  • Materiality is intended to provoke discussion and interest among architects and designers, professionals and students, and the general reader.
  • This year's edition, Materiality: Brick in contemporary university architecture, highlights how architects and designers are using brick in campus and community architectural projects across the United States.
  • The exclusive event will include a discussion, "Shapes to the X Degree," featuring several architects from across the U.S.
  • "The latest edition of Materiality showcases the multifaceted role of brick beyond its function as a mere building block.

Westinghouse Announces Executive Management Appointments

Retrieved on: 
Lunedì, Aprile 1, 2024
Other Energy, Environment, Utilities, Green Technology, Energy, Nuclear, Mechanical, Connectivity, Quality control, Health, General Electric, Westinghouse Electric Company, Mechanics, Engineering science and mechanics, Mechanical engineering, Business, CommScope, Aviation, Transport, University, Diaphragm, MBA, HS, University of Rochester, Engineering, Pennsylvania State University, Nuclear energy, Safety, Retirement, Multimedia, University of La Verne, Management

View the full release here: https://www.businesswire.com/news/home/20240401801853/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240401801853/en/
    Ron Timperio is appointed Chief Operating Officer and Executive Vice President, Global Operations Services
    Adam Silverstein is appointed Executive Vice President, Quality, Environment, Health & Safety
    “Strong execution across our global operations coupled with the highest standards of safety and quality is critical for both our day-to-day and long-term success,” said Patrick Fragman, Westinghouse President and Chief Executive Officer.
  • “Ron is a seasoned executive who brings to Westinghouse an unrelenting focus on performance and delivery through diverse, cross-functional experience across global industries.
  • He has 30 years of experience in manufacturing operations; supply chain management; environmental, health and safety; and quality control.
  • Adam Silverstein appointed Executive Vice President, Quality, Environment, Health & Safety
    Mr. Silverstein will lead Westinghouse’s nuclear safety, industrial safety and quality assurance programs.

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Retrieved on: 
Mercoledì, Gennaio 24, 2024
SAN, Standard of care, Fluorescence, University of Rochester, Test management, University, SVS, FISH, Genomics, DSM-IV codes, In situ hybridization, IRB, SOC, Karyotype, CMA, KT, Columbia University, OGM, Clinical trial, Institutional review board, Data, Diagnosis, Medical device

This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.

Key Points: 
  • This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.
  • This second interim readout is designed to evaluate endpoints connected to analytical performance using an expanded dataset in key areas of technical performance and clinical utility of OGM.
  • The study is an Institutional Review Board (IRB)-approved, multicenter, double-blinded trial with samples from 219 unique retrospective (57) and prospective (162) clinical research subjects.
  • All samples had been previously tested with traditional methods including karyotyping (KT), fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA).

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing

Retrieved on: 
Giovedì, Gennaio 11, 2024
ASD, Patient, Medical college, Spectrum, DSM-IV codes, SAN, Standard of care, University of Rochester, University, Genomics, SOC, OGM, Intellectual disability, Diagnosis, Trial of the century

The clinical study is designed to compare OGM to current SOC techniques, including concordance, reproducibility, technical success rate and the rate of detecting reportable findings in cases.

Key Points: 
  • The clinical study is designed to compare OGM to current SOC techniques, including concordance, reproducibility, technical success rate and the rate of detecting reportable findings in cases.
  • The published first phase of this multisite study demonstrated OGM’s technical performance and reproducibility across sites versus SOC analysis.
  • This second phase extended the study to include additional samples to further assess the technical performance and clinical utility of OGM for postnatal constitutional disorders and to evaluate OGM in prospective samples and in samples from subjects with neurodevelopmental disorders, including developmental delay, intellectual disability and autism spectrum disorder (ASD).
  • The key findings are:
    OGM increased the rate of finding pathogenic or likely pathogenic (P/LP) variants over that of SOC by a factor of 6% to as much as 50% depending on the patient population as outlined below:

SolasCure Demonstrates Proof-of-Concept in Phase lla Safety Trial of Aurase Wound Gel

Retrieved on: 
Martedì, Dicembre 12, 2023
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Medical Devices, Clinical Trials, Harvard University, Safety, Simon Business School, University of Zurich, Senior, Erythema, INN, EIC, Patient, University of Rochester, Regenerative medicine, Medical Affairs Bureau, Wound healing, MBA, Bleeding, University, Phase, Debridement, Growth, Medicine, Doctor of Philosophy, Edema, Hydrogel, Pharmaceutical industry, Nursing, Boston, Dermatology

The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).

Key Points: 
  • The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).
  • SolasCure’s CLEANVLU Phase IIa clinical trial observed a strong safety profile for Aurase Wound Gel, with no evidence of systemic availability, no antibody generation to the enzyme and no effects on systemic coagulation pathways.
  • SolasCure’s Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots, aims to facilitate debridement, reduce bacterial biofilm, and promote wound bed preparation and healing.
  • Aurase Wound Gel is due to enter further Phase II trials to further evaluate its efficacy across a larger and more diverse patient group than the Phase IIa study, with the positive safety data obtained from the Phase IIa trial allowing for higher concentrations of the gel to now be explored.